Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

CDC panel expands RSV vaccine recommendations for at-risk adults aged 50-59, including Pfizer's Abrysvo. Read more here.

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Guidelines from the Advisory Committee on Immunization Practices help physicians decide what vaccines to recommend to ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

Johnson & Johnson will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a Fireside Chat at 1:35 p.m. Eastern Time. This ...

Clearwater Analytics Holdings, Inc. , ("Clearwater Analytics" or the "Company"), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today ...

Pfizer Inc. has announced the company has discontinued the development of danuglipron (PF-06882961), an oral glucagon-like ...